The influence of pyrazinamide resistant associated gene mutations on multidrug-resistant mycobacterium tuberculosis in China

Author:

Zhang Yuzhen1,Li Yifan2,Liu Yao1,Kong Xianglong3,Li Huaichen1,Wang Tingting4,Li Yameng4,Zhu Xuehan1,An Qiqi5,Han Qilin1,Fang Weiwei1,Li Yingying4,Long Fei2,Tao Ningning1

Affiliation:

1. Shandong Provincial Hospital, Shandong University, Shandong Provincial Hospital Affiliated to Shandong First Medical University

2. The Third Affiliated Hospital of Shandong First Medical University (Affiliated Hospital of Shandong Academy of Medical Sciences)

3. Qilu University of Technology (Shandong Academy of Sciences)

4. Shandong University of Traditional Chinese Medicine

5. XingYi People's Hospital

Abstract

Abstract Background Pyrazinamide (PZA) is essential for the treatment of drug-susceptible and drug-resistant tuberculosis (TB), especially multidrug-resistant (MDR) TB, but the condition of PZA resistance (PZA-R) across China is unknown. Our aim is to clarify the genetic mutations of PZA-R and the relationship between PZA-R and MDR-TB in China, from 2007 to 2019. Methods A total of 3202 TB strains with gene sequences results in China were included, among which 1447 strains were sequenced and 1775 were download from the European Nucleic Acid Sequence Database. Drug resistance was investigated by detecting resistance-conferring mutations. A phylogenetic tree was constructed to illustrate the genetic structure of the TB strains. Fisher's exact or Pearson's chi-square tests, as well as logistic regression analysis were used for correlation analysis. Those were calculated by SPSS software. Results All the 3202 strains were divided into four lineages (L1, L2, L3, L4), most belonged to L2 (2745, 85.7%), followed by L4 (443, 13.8%), the rest L1 plus L3 (14, 0.4%). About 45.6% (n = 1459) strains referred to isoniazid resistance (INH-R), 43.4% (n = 1389) rifampicin resistance (RIF-R), and 40.5% (n = 1296) MDR. There were 591 isolates resistant to PZA, among which 96.1% (n = 568) were also MDR. The rate of PZA-R was 43.8% (568/1296) among MDR isolates. The trends of PZA-R fluctuated in accordance with the trends of MDR, INH-R, RIF-R during 2007–2019. Up to 254 kinds of mutations associated with PZA-R were found, with 16.5% (n = 42) isolates harboring ≥ 2 PZA-R associated mutations. Codons 11 (encoding pncA_c.011A > G, n = 30, 11.8%), 76 (encoding pncA_p.Thr76Pro, n = 13, 5.1%), and 139 (encoding pncA_p.Val139Leu, n = 13, 5.1%) were the top three PZA-R associated mutation sites. All PZA-R mutation sites accounting at least 1% were included to analyse the influence of PZA-R on other drug resistance (MDR, INH-R, RIF-R). Finally, three PZA-R related mutations (pncA_p.Val139Ala, pncA_p.Thr47Ala, pncA_p.Leu85Pro) were associated with MDR, four were associate with (pncA_p.Thr76Pro, pncA_p.Val139Ala, pncA_p.Thr47Ala, pncA_p.Leu85Pro) INH-R and none was associated with RIF-R. Conclusion PZA-R especially gene mutation referred to pncA region may promote MDR, this phenomenon mainly associated with the function of PZA-R on INH-R. It is important to consider PZA-R particularly the three associated mutations (pncA region associated mutations) into consideration in treating MDR-TB and explore its mechanism.

Publisher

Research Square Platform LLC

Reference50 articles.

1. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update;Falzon D;EUR RESPIR J,2011

2. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis;Gandhi NR;Lancet,2010

3. Pyrazinamide resistance in Mycobacterium tuberculosis: Review and update;Njire M;ADV MED SCI-POLAND,2016

4. ©. 1996 Nature Publishing Group http://www.nature.com/naturemedicine.

5. PYRAZINAMIDE SUSCEPTIBILITY. AND AMIDASE ACTIVITY OF TUBERCLE BACILLJl. 2.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3